Letrozole

Generic Name: Letrozole

Brand Names: Femara, Kisqali Femara Co-pack

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₁N_₅

CAS Number: 112809-51-5

Unique Ingredient Identifier: 7LKK855W8I

Background: Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.

Letrozole was granted FDA approval on 25 July 1997.

Indication: Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.

Associated Conditions: Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer

Associated Therapies: -

Clinical Trials

Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

Early Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Letrozole
Dietary Supplement: Fish Oil

First Posted Date: 2015-09-02

Last Posted Date: 2023-07-17

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 24

Registration Number: NCT02538484

Locations: 🇺🇸
Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States
🇺🇸
Houston Methodist Cancer Center at Texas Medical Center, Houston, Texas, United States

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Letrozole
Drug: Everolimus
Drug: TRC105

First Posted Date: 2015-08-11

Last Posted Date: 2023-12-29

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 15

Registration Number: NCT02520063

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Phase 1

Active, not recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: Palbociclib
Drug: Letrozole

First Posted Date: 2015-07-15

Last Posted Date: 2024-09-30

Lead Sponsor: Pfizer

Target Recruit Count: 26

Registration Number: NCT02499146

Locations: 🇨🇳
The first hospital of jilin university, Changchun, Jilin, China
🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
Beijing Cancer Hospital/Oncology department, Beijing, Beijing, China

and more 4 locations

The Clinical Trial of Acupuncture Pre-treatment on PCOS

Phase 3

Completed

Conditions: Polycystic Ovary Syndrome

Interventions: Other: Pre-treatment acupuncture
Drug: Letrozole

First Posted Date: 2015-07-08

Last Posted Date: 2021-06-23

Lead Sponsor: The First Affiliated Hospital of Guangzhou Medical University

Target Recruit Count: 384

Registration Number: NCT02491320

Locations: 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Palbociclib
Drug: Letrozole
Drug: Fulvestrant

First Posted Date: 2015-07-08

Last Posted Date: 2024-12-09

Lead Sponsor: MedSIR

Target Recruit Count: 486

Registration Number: NCT02491983

Locations: 🇪🇸
MedSIR investigative site B, Zaragoza, Spain
🇬🇧
MedSIR investigative site, Truro, United Kingdom

A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix

Phase 2

Conditions: Uterine Cervical Neoplasms

Interventions: Drug: Letrozole
Drug: tamoxifen

First Posted Date: 2015-06-26

Last Posted Date: 2015-06-26

Lead Sponsor: Buddhist Tzu Chi General Hospital

Target Recruit Count: 44

Registration Number: NCT02482740

Locations: 🇨🇳
Dept. of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, No 123, Dapi Rd, Niaosong Dist, Taiwan
🇨🇳
China Medical University Hospital, Taichung, No.2, Yude Rd., North Dist.,, Taiwan
🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, No.100, Ziyou 1st Rd., Sanmin Dist., Taiwan

and more 4 locations